Immunotherapy for cardiovascular disease
The outcomes of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial have unequivocally proven that inflammation is a key driver of atherosclerosis and that targeting inflammation, in this case by using an anti-interleukin-1β antibody, improves cardiovascular disease (CVD) outco...
Uloženo v:
| Vydáno v: | European heart journal Ročník 40; číslo 48; s. 3937 |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
21.12.2019
|
| Témata: | |
| ISSN: | 1522-9645, 1522-9645 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | The outcomes of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial have unequivocally proven that inflammation is a key driver of atherosclerosis and that targeting inflammation, in this case by using an anti-interleukin-1β antibody, improves cardiovascular disease (CVD) outcomes. This is especially true for CVD patients with a pro-inflammatory constitution. Although CANTOS has epitomized the importance of targeting inflammation in atherosclerosis, treatment with canakinumab did not improve CVD mortality, and caused an increase in infections. Therefore, the identification of novel drug targets and development of novel therapeutics that block atherosclerosis-specific inflammatory pathways and exhibit limited immune-suppressive side effects, as pursued in our collaborative research centre, are required to optimize immunotherapy for CVD. In this review, we will highlight the potential of novel immunotherapeutic targets that are currently considered to become a future treatment for CVD. |
|---|---|
| AbstractList | The outcomes of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial have unequivocally proven that inflammation is a key driver of atherosclerosis and that targeting inflammation, in this case by using an anti-interleukin-1β antibody, improves cardiovascular disease (CVD) outcomes. This is especially true for CVD patients with a pro-inflammatory constitution. Although CANTOS has epitomized the importance of targeting inflammation in atherosclerosis, treatment with canakinumab did not improve CVD mortality, and caused an increase in infections. Therefore, the identification of novel drug targets and development of novel therapeutics that block atherosclerosis-specific inflammatory pathways and exhibit limited immune-suppressive side effects, as pursued in our collaborative research centre, are required to optimize immunotherapy for CVD. In this review, we will highlight the potential of novel immunotherapeutic targets that are currently considered to become a future treatment for CVD. The outcomes of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial have unequivocally proven that inflammation is a key driver of atherosclerosis and that targeting inflammation, in this case by using an anti-interleukin-1β antibody, improves cardiovascular disease (CVD) outcomes. This is especially true for CVD patients with a pro-inflammatory constitution. Although CANTOS has epitomized the importance of targeting inflammation in atherosclerosis, treatment with canakinumab did not improve CVD mortality, and caused an increase in infections. Therefore, the identification of novel drug targets and development of novel therapeutics that block atherosclerosis-specific inflammatory pathways and exhibit limited immune-suppressive side effects, as pursued in our collaborative research centre, are required to optimize immunotherapy for CVD. In this review, we will highlight the potential of novel immunotherapeutic targets that are currently considered to become a future treatment for CVD.The outcomes of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial have unequivocally proven that inflammation is a key driver of atherosclerosis and that targeting inflammation, in this case by using an anti-interleukin-1β antibody, improves cardiovascular disease (CVD) outcomes. This is especially true for CVD patients with a pro-inflammatory constitution. Although CANTOS has epitomized the importance of targeting inflammation in atherosclerosis, treatment with canakinumab did not improve CVD mortality, and caused an increase in infections. Therefore, the identification of novel drug targets and development of novel therapeutics that block atherosclerosis-specific inflammatory pathways and exhibit limited immune-suppressive side effects, as pursued in our collaborative research centre, are required to optimize immunotherapy for CVD. In this review, we will highlight the potential of novel immunotherapeutic targets that are currently considered to become a future treatment for CVD. |
| Author | Weber, Christian Atzler, Dorothee Steffens, Sabine Lutgens, Esther Duchene, Johan Döring, Yvonne |
| Author_xml | – sequence: 1 givenname: Esther surname: Lutgens fullname: Lutgens, Esther organization: German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany – sequence: 2 givenname: Dorothee surname: Atzler fullname: Atzler, Dorothee organization: Walther-Straub Institute of Pharmacology and Toxicology, Ludwig-Maximilians-Universität, Goethestraße 33, Munich 80336, Germany – sequence: 3 givenname: Yvonne surname: Döring fullname: Döring, Yvonne organization: German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany – sequence: 4 givenname: Johan surname: Duchene fullname: Duchene, Johan organization: German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany – sequence: 5 givenname: Sabine surname: Steffens fullname: Steffens, Sabine organization: German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany – sequence: 6 givenname: Christian surname: Weber fullname: Weber, Christian organization: Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Universiteitsingel 50, 6229 ER Maastricht, the Netherlands |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31121017$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNj8tLAzEYxINU7EPvnmSPvazNl2zT7FGKj0LBi56XL5sv7JZ9mWyE-tdbsYKHYebwY5iZs0nXd8TYLfB74LlcUfQVoR8PK6q-hJYXbAZrIdJcZevJvzxl8xAOnHOtQF2xqQQQwGEzY8td28auHyvyOBwT1_ukRG_r_hNDGRv0ia0DYaBrdumwCXRz9gV7f3p8276k-9fn3fZhn5YZhzFFUMQzpZy0aMFyAzIDqa0xYBzk4DgqIouZLu1pC9cEmms04PRJBsSCLX97B99_RApj0dahpKbBjvoYCiGkALER4ge9O6PRtGSLwdct-mPx9058A0leVQE |
| CitedBy_id | crossref_primary_10_1093_eurheartj_ehaa160 crossref_primary_10_3389_fcvm_2021_812702 crossref_primary_10_1038_s41569_023_00986_9 crossref_primary_10_1111_jcmm_16566 crossref_primary_10_3389_fimmu_2022_1053175 crossref_primary_10_3390_genes13030468 crossref_primary_10_1016_j_nano_2021_102421 crossref_primary_10_1016_j_nano_2023_102700 crossref_primary_10_3390_foods10112891 crossref_primary_10_18087_cardio_2022_11_n2283 crossref_primary_10_1016_j_phrs_2022_106157 crossref_primary_10_1161_CIRCRESAHA_122_321094 crossref_primary_10_1097_MOL_0000000000000852 crossref_primary_10_1016_j_jtha_2023_01_028 crossref_primary_10_1042_BSR20230124 crossref_primary_10_1093_eurheartj_ehad304 crossref_primary_10_1016_j_jacc_2019_07_061 crossref_primary_10_3390_biomedicines12122842 crossref_primary_10_3390_nu16091321 crossref_primary_10_1111_jgs_19018 crossref_primary_10_1016_j_clim_2022_109013 crossref_primary_10_1038_s41577_021_00557_4 crossref_primary_10_1002_jcp_31192 crossref_primary_10_3389_fendo_2022_933635 crossref_primary_10_1161_JAHA_122_026036 crossref_primary_10_3389_fcvm_2022_864602 crossref_primary_10_1111_cpr_13725 crossref_primary_10_1002_cbin_11678 crossref_primary_10_1186_s13244_025_01907_9 crossref_primary_10_2147_IJGM_S328882 crossref_primary_10_1007_s12181_022_00542_8 crossref_primary_10_1038_s42003_025_07453_w crossref_primary_10_3389_fimmu_2020_00743 crossref_primary_10_1186_s12967_022_03562_w crossref_primary_10_1007_s00395_021_00849_9 crossref_primary_10_1016_j_jaccao_2022_11_011 crossref_primary_10_7759_cureus_42790 crossref_primary_10_1038_s41598_025_94507_y crossref_primary_10_1186_s13020_023_00874_x crossref_primary_10_1093_ehjopen_oead013 crossref_primary_10_1002_ctm2_1040 crossref_primary_10_1093_eurheartj_ehac094 crossref_primary_10_3892_br_2023_1637 crossref_primary_10_1016_j_trim_2022_101652 crossref_primary_10_3390_cells10092435 crossref_primary_10_3389_fmolb_2022_940465 crossref_primary_10_3390_cells13181589 crossref_primary_10_2147_JIR_S439315 crossref_primary_10_1016_j_atherosclerosis_2021_09_024 crossref_primary_10_1039_D1FO00991E crossref_primary_10_1093_cvr_cvae125 crossref_primary_10_3389_fcvm_2020_00106 crossref_primary_10_1002_dad2_12491 crossref_primary_10_1007_s11883_020_00874_4 crossref_primary_10_1007_s12265_021_10169_x crossref_primary_10_1093_eurheartj_ehz717 crossref_primary_10_1016_j_cjca_2022_05_013 crossref_primary_10_1186_s41043_023_00478_z crossref_primary_10_1093_infdis_jiac186 crossref_primary_10_1016_j_gene_2023_148042 crossref_primary_10_1080_21655979_2021_1967066 crossref_primary_10_3389_fcvm_2023_1061119 crossref_primary_10_1016_j_atherosclerosis_2024_118616 crossref_primary_10_36290_vnl_2021_078 crossref_primary_10_1016_j_jpsychores_2023_111480 crossref_primary_10_3390_life14050571 crossref_primary_10_1038_s41598_024_83733_5 crossref_primary_10_1186_s13073_025_01456_2 crossref_primary_10_1186_s11671_021_03609_9 crossref_primary_10_1093_qjmed_hcab207 crossref_primary_10_1038_s41401_020_00580_6 crossref_primary_10_3389_fcvm_2023_1038738 crossref_primary_10_1016_j_tjnut_2023_02_031 crossref_primary_10_1093_eurheartj_ehz928 crossref_primary_10_1016_j_ijcard_2020_03_056 crossref_primary_10_1126_scitranslmed_adf3357 crossref_primary_10_3390_jcm10245907 crossref_primary_10_1016_j_jconrel_2023_01_024 crossref_primary_10_1038_s41573_021_00198_1 crossref_primary_10_1089_mab_2025_0005 crossref_primary_10_1093_qjmed_hcab173 crossref_primary_10_1016_j_phrs_2022_106236 crossref_primary_10_1016_j_intimp_2024_113803 crossref_primary_10_3389_fcvm_2023_1091950 crossref_primary_10_1016_j_apsb_2020_12_018 crossref_primary_10_1161_CIRCULATIONAHA_119_042276 crossref_primary_10_1016_j_jacbts_2025_04_014 crossref_primary_10_1055_a_1539_8664 crossref_primary_10_1093_bib_bbab322 crossref_primary_10_3390_antib12030051 crossref_primary_10_3390_antiox12122073 crossref_primary_10_1093_cvr_cvac084 crossref_primary_10_1007_s10741_020_09934_y crossref_primary_10_1016_j_joim_2024_11_002 crossref_primary_10_1111_jdi_13899 crossref_primary_10_1186_s12906_025_04760_x crossref_primary_10_1016_j_humimm_2023_06_002 crossref_primary_10_1038_s41423_020_00586_4 crossref_primary_10_3389_fphar_2020_610550 crossref_primary_10_1016_j_envres_2025_122382 crossref_primary_10_1038_s41569_024_01023_z crossref_primary_10_3390_transplantology3020017 crossref_primary_10_3389_fphys_2021_666449 crossref_primary_10_1016_j_ijcard_2020_05_008 crossref_primary_10_1038_s44161_023_00413_9 crossref_primary_10_3389_fphys_2023_1110926 crossref_primary_10_7717_peerj_18129 crossref_primary_10_1186_s12964_023_01077_5 crossref_primary_10_1161_CIRCRESAHA_121_319077 crossref_primary_10_1186_s13073_024_01350_3 crossref_primary_10_3390_biomedicines13071586 crossref_primary_10_2217_imt_2021_0009 crossref_primary_10_1016_j_phrs_2022_106533 crossref_primary_10_1186_s13020_020_0286_1 crossref_primary_10_17816_mechnikov637317 crossref_primary_10_1016_j_jep_2023_116219 crossref_primary_10_1002_advs_202102330 crossref_primary_10_1038_s41440_024_01661_3 crossref_primary_10_1002_mdr2_70007 crossref_primary_10_1161_ATVBAHA_120_315448 crossref_primary_10_1186_s12967_024_05537_5 crossref_primary_10_1038_s41598_024_76190_7 crossref_primary_10_1038_s41598_025_16948_9 crossref_primary_10_1016_j_tice_2025_102932 crossref_primary_10_1038_s41467_020_19764_z crossref_primary_10_1093_eurheartj_ehz919 crossref_primary_10_15212_AMM_2024_0046 crossref_primary_10_1016_j_jad_2022_01_106 crossref_primary_10_1038_s41598_020_58374_z crossref_primary_10_12677_tcm_2024_134132 crossref_primary_10_1016_j_ejim_2024_05_016 crossref_primary_10_3389_fimmu_2022_975367 crossref_primary_10_3390_biom11071047 crossref_primary_10_3389_fmed_2022_941422 crossref_primary_10_3390_ijms222111419 |
| ContentType | Journal Article |
| Copyright | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com. |
| Copyright_xml | – notice: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com. |
| DBID | NPM 7X8 |
| DOI | 10.1093/eurheartj/ehz283 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1522-9645 |
| ExternalDocumentID | 31121017 |
| Genre | Journal Article |
| GroupedDBID | --- -E4 .2P .I3 .XZ .ZR 08P 0R~ 18M 1TH 29G 2WC 4.4 482 48X 53G 5GY 5RE 5VS 5WA 5WD 70D AABZA AACZT AAJKP AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AAUAY AAUQX AAVAP ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABNHQ ABNKS ABOCM ABPTD ABQLI ABQNK ABVGC ABWST ABXVV ABZBJ ACGFO ACGFS ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFXAL AFXEN AGINJ AGKEF AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AIAGR AIJHB AJEEA ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APWMN ATGXG AXUDD BAWUL BAYMD BCGUY BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CDBKE CS3 CZ4 DAKXR DIK DILTD D~K E3Z EBS EE~ EMOBN ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IOX J21 KAQDR KBUDW KOP KQ8 KSI KSN L7B M-Z M41 M49 MHKGH ML0 N9A NGC NOMLY NOYVH NPM NU- O9- OAUYM OAWHX OB3 OCZFY ODMLO OGROG OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q1. Q5Y R44 RD5 ROL ROX ROZ RUSNO RW1 RXO SEL TCURE TEORI TJX W8F WOQ X7H YAYTL YKOAZ YXANX ZKX ~91 7X8 AAFWJ ABPQP ADGHP ADNBA AEMQT AFYAG AHGBF AJBYB AJNCP ALXQX JXSIZ |
| ID | FETCH-LOGICAL-c401t-a16e0466f3dad1d0b134138dbb1bf191f0a6eeda48cd61608e1808ab1f8b1fb12 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 138 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000506834300014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1522-9645 |
| IngestDate | Sat Sep 27 22:14:57 EDT 2025 Wed Feb 19 02:31:52 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 48 |
| Keywords | Cardiovascular disease Inflammation Cytokines Novel targets Novel therapies Coronary artery disease |
| Language | English |
| License | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c401t-a16e0466f3dad1d0b134138dbb1bf191f0a6eeda48cd61608e1808ab1f8b1fb12 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 31121017 |
| PQID | 2232127221 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2232127221 pubmed_primary_31121017 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-12-21 |
| PublicationDateYYYYMMDD | 2019-12-21 |
| PublicationDate_xml | – month: 12 year: 2019 text: 2019-12-21 day: 21 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | European heart journal |
| PublicationTitleAlternate | Eur Heart J |
| PublicationYear | 2019 |
| SSID | ssj0008616 |
| Score | 2.6248953 |
| SecondaryResourceType | review_article |
| Snippet | The outcomes of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial have unequivocally proven that inflammation is a key driver of... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 3937 |
| Title | Immunotherapy for cardiovascular disease |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31121017 https://www.proquest.com/docview/2232127221 |
| Volume | 40 |
| WOSCitedRecordID | wos000506834300014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEB7UFfHi-7G-qODBS9mmaZvkJCIuethlDwp7K3miHtp1H4L-eifdLIsHQfDQ3gplMsnMly_5PoArS5mzrMhjzbRGgGJ0LEzhB8SIXHKtlXCN2QTr9_lwKAZhw20SjlUu1sRmoTa19nvkHSxjXow8TcnN6D32rlGeXQ0WGqvQotjK-Kxmw6VaOC8a61MsUWksiiwPNCWC-I6djb1j9PStY1--Ui8a-FuD2RSa7vZ_f3EHtkKLGd3Oc2IXVmy1Bxu9QKLvw_WjvxMSbl59Rti1RvrHqdQosDYH8Ny9f7p7iINhQqwRJk1jSQqLeLdw1EhDTKK8WhvlRimiHAIzl8gCa6LMuDYYmoRbwhMuFXEcH0XSQ1ir6soeQ6QTnStjqaBCZ4wJ6bJEWoQ7LuNKZaINl4sYlJiQnmWQla1nk3IZhTYczQNZjubKGSUlXq-MsJM_fH0Km9icNF4NKTmDlsPpaM9hXX9MXyfji2ak8d0f9L4Bliu02w |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Immunotherapy+for+cardiovascular+disease&rft.jtitle=European+heart+journal&rft.au=Lutgens%2C+Esther&rft.au=Atzler%2C+Dorothee&rft.au=D%C3%B6ring%2C+Yvonne&rft.au=Duchene%2C+Johan&rft.date=2019-12-21&rft.issn=1522-9645&rft.eissn=1522-9645&rft.volume=40&rft.issue=48&rft.spage=3937&rft_id=info:doi/10.1093%2Feurheartj%2Fehz283&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1522-9645&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1522-9645&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1522-9645&client=summon |